Over the projection period, it is anticipated that rising cancer rates would spur market expansion for proton treatment. For instance, the World Health Organisation reports that in 2018, there were around 18.1 million new cases of cancer and 9.6 million cancer-related deaths worldwide. Additionally, a growing number of healthcare facilities that offer proton treatment are anticipated to support market expansion. For instance, the Illinois Health Facilities and Services Review Board gave its approval to OSF HealthCare's intention to build a cancer treatment facility that delivers proton beam therapy in February 2020.
The Single Room segment of the global market for Proton Therapy was valued at US$ 407.3 Mn in 2019 and is anticipated to grow at a CAGR of 11.6% to reach US$ 980.0 Mn by 2027.
Leading Companies in the Proton Therapy Industry:
1. Hitachi Ltd.: Hitachi High-Tech Corp integrates its manufacturing and trading operations to create high-tech solutions. Process equipment, social infrastructure inspection equipment, electron microscopes, industrial solutions, and industrial components and materials make up the majority of the company's offerings. created in 1947. Head office in Japan. A leading U.S.-based provider of digital engineering services, GlobalLogic, will be acquired by Hitachi, the company said in 2021.
2. Ion Beam Applications SA; Started in 1986. Headquarters at Belgium's Louvain-La-Neuve. Ion Beam Applications SA designs and produces software and medical equipment. The company has two business divisions: dosimetry and other accelerators and proton therapy. The majority of sales are attributed to proton therapy and other accelerator businesses. Ion Beam Applications SA ("IBA") therefore discloses information regarding its share repurchase programme, which was launched on December 3rd, 2021, in line with article 8:4 of the Royal Decree of 29 April 2019 implementing the Belgian Code on Companies and Associations.
3. Mevion Medical Systems: Created in 2004. Developer of proton therapy systems with global headquarters for cancer patients. The company's products incorporate patented technology at the cutting edge of proton therapy to deliver greater beam quality and uptime, allowing cancer centres and physicians to minimise system size and complexity, increase throughput and dependability, and lower capital and operational costs. Mevion Medical Systems, Inc. announced the successful completion of a $150 million financing transaction that was backed by a number of preexisting investors, including HOPU Investments and China Everbright Limited and was led by YuanMing Capital and other private equity investors, including Henan Maisheng Medical Technology Co., Ltd.